Literature DB >> 24399507

Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells.

Joanna Pyszko1, Joanna B Strosznajder.   

Abstract

Sphingosine kinases (Sphk1/2) are crucial enzymes in regulation of the biostat between sphingosine-1-phosphate (S1P) and ceramide and play an important role in the pathogenesis/pathomechanism of Alzheimer's disease (AD). These enzymes synthesise S1P, which regulates neurotransmission, synaptic function and neuron cell proliferation, by activating five G protein-coupled receptors (S1P1-5). However, S1P synthesised by Sphk2 could be involved in amyloid β (Aβ) release by stimulation of Aβ precursor protein degradation. The significance of this bioactive sphingolipid in the pathogenesis of Parkinson's disease (PD) is unknown. The aim of our study was to investigate the expression level of Sphk1 and its role in human dopaminergic neuronal cell (SH-SY5Y) viability under oxidative stress, evoked by 1-methyl-4-phenylpyridinium (MPP+). Moreover, the mechanism of S1P action on the death signalling pathway in these experimental conditions was evaluated. Our study indicated marked downregulation of Sphk1 expression in this cellular PD model. Inhibition of Sphk1 decreased SH-SY5Y cell viability and concomitantly enhanced the reactive oxygen species (ROS) level. It was found that exogenous S1P (1 μM) exerted the neuroprotective effect by activation of Sphk1 and S1P1 receptor gene expression. Moreover, S1P downregulated Bax and harakiri, death protein 5 (Hrk/DP5) expression and enhanced cell viability in MPP+-treated cells. The neuroprotective mechanism of S1P is mainly dependent on S1P1 receptor signalling, which was indicated by using specific agonists and antagonists of S1P1 receptor. The results show that S1P and S1P1 receptor agonists protected a significant population of neuronal cells against death.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24399507     DOI: 10.1007/s12035-013-8622-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  76 in total

1.  Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production.

Authors:  Zhi-Guo Zhang; Lin Wu; Ju-Lei Wang; Jian-Dong Yang; Jing Zhang; Jian Zhang; Li-Hong Li; Yi Xia; Li-Bo Yao; Huai-Zhou Qin; Guo-Dong Gao
Journal:  Mol Cell Biochem       Date:  2012-01-26       Impact factor: 3.396

2.  Fingolimod provides long-term protection in rodent models of cerebral ischemia.

Authors:  Ying Wei; Muge Yemisci; Hyung-Hwan Kim; Lai Ming Yung; Hwa Kyoung Shin; Seo-Kyoung Hwang; Shuzhen Guo; Tao Qin; Nafiseh Alsharif; Volker Brinkmann; James K Liao; Eng H Lo; Christian Waeber
Journal:  Ann Neurol       Date:  2010-11-12       Impact factor: 10.422

3.  The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells.

Authors:  Katy E Beck; Luigi A De Girolamo; Martin Griffin; E Ellen Billett
Journal:  Neurosci Lett       Date:  2006-07-28       Impact factor: 3.046

4.  Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.

Authors:  Kazuaki Takabe; Roger H Kim; Jeremy C Allegood; Poulami Mitra; Subramaniam Ramachandran; Masayuki Nagahashi; Kuzhuvelil B Harikumar; Nitai C Hait; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

5.  Disrupted mitochondrial electron transport function increases expression of anti-apoptotic bcl-2 and bcl-X(L) proteins in SH-SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress.

Authors:  G A Veech; J Dennis; P M Keeney; C P Fall; R H Swerdlow; W D Parker; J P Bennett
Journal:  J Neurosci Res       Date:  2000-09-15       Impact factor: 4.164

Review 6.  Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism.

Authors:  Dagmar Meyer zu Heringdorf; Karl H Jakobs
Journal:  Biochim Biophys Acta       Date:  2006-10-04

7.  Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells.

Authors:  Isabelle Ader; Leyre Brizuela; Pierre Bouquerel; Bernard Malavaud; Olivier Cuvillier
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  Sphingosine kinase activation mediates ischemic preconditioning in murine heart.

Authors:  Zhu-Qiu Jin; Edward J Goetzl; Joel S Karliner
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

Review 9.  Regulation of the sphingosine kinase/sphingosine 1-phosphate pathway.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Handb Exp Pharmacol       Date:  2013

10.  Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?

Authors:  Pavel Katsel; Celeste Li; Vahram Haroutunian
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

View more
  28 in total

1.  Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.

Authors:  Jean-Philip Truman; Christian F Ruiz; Magali Trayssac; Cungui Mao; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191

2.  Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.

Authors:  Ireen Denya; Sarel F Malan; Adaze B Enogieru; Sylvester I Omoruyi; Okobi E Ekpo; Erika Kapp; Frank T Zindo; Jacques Joubert
Journal:  Medchemcomm       Date:  2018-01-16       Impact factor: 3.597

3.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

Review 4.  Sepsis-Associated Encephalopathy: The Blood-Brain Barrier and the Sphingolipid Rheostat.

Authors:  Stephen J Kuperberg; Raj Wadgaonkar
Journal:  Front Immunol       Date:  2017-06-16       Impact factor: 7.561

5.  Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson's disease.

Authors:  Na Zhang; Chuanxi Tang; Qiong Ma; Wei Wang; Mingyu Shi; Xiaoyu Zhou; Fangfang Chen; Chengcheng Ma; Xue Li; Gang Chen; Dianshuai Gao
Journal:  Ann Transl Med       Date:  2021-04

Review 6.  Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease.

Authors:  Joanna A Motyl; Joanna B Strosznajder; Agnieszka Wencel; Robert P Strosznajder
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

7.  Sphingosine-1-phosphate and its effect on glucose deprivation/glucose reload stress: from gene expression to neuronal survival.

Authors:  Kinga Czubowicz; Magdalena Cieślik; Joanna Pyszko; Joanna B Strosznajder; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2014-07-24       Impact factor: 5.590

8.  The Molecular Mechanism of Amyloid β42 Peptide Toxicity: The Role of Sphingosine Kinase-1 and Mitochondrial Sirtuins.

Authors:  Magdalena Cieślik; Grzegorz A Czapski; Joanna B Strosznajder
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

Review 9.  Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate.

Authors:  Norishi Ueda
Journal:  Int J Mol Sci       Date:  2015-03-05       Impact factor: 5.923

10.  Neural ablation of the PARK10 candidate Plpp3 leads to dopaminergic transmission deficits without neurodegeneration.

Authors:  Sandra Gómez-López; Ana Valeria Martínez-Silva; Teresa Montiel; Daniel Osorio-Gómez; Federico Bermúdez-Rattoni; Lourdes Massieu; Diana Escalante-Alcalde
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.